CytomX Therapeutics (CTMX) Research & Development (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Research & Development came in at $19.2 million in Q1 2026, up 1.96% YoY from $18.9 million in Q1 2025, and down 9.4% on a QoQ basis from $21.2 million in Q4 2025.
CytomX Therapeutics (CTMX) Research & Development (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Research & Development data on file, last reported at $19.2 million in Q1 2026.
- Quarterly Research & Development rose 1.96% year-over-year to $19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (down 13.84% YoY) and the FY2025 annual result came in at $68.7 million, down 17.57% from the prior year.
- Research & Development slipped to $19.2 million in Q1 2026, from $21.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $31.2 million in Q2 2022 to a low of $13.3 million in Q2 2025.
- A 5-year average of $21.2 million and a median of $20.7 million in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 43.58% in 2025, down 47.08% in 2025.
- Tracing CTMX's Research & Development over 5 years: stood at $19.6 million in 2022, then declined by 0.91% to $19.4 million in 2023, then retreated by 23.71% to $14.8 million in 2024, then surged by 43.58% to $21.2 million in 2025, then retreated by 9.4% to $19.2 million in 2026.
- The last three Research & Development figures came in at $19.2 million (Q1 2026), $21.2 million (Q4 2025), and $15.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 17.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.60 Mn |
| Mar 31, 2026 | 19.24 Mn |
| Dec 31, 2025 | 21.24 Mn |
| Sep 30, 2025 | 15.30 Mn |
| Jun 30, 2025 | 13.32 Mn |
| Mar 31, 2025 | 18.87 Mn |
| Dec 31, 2024 | 14.79 Mn |
| Sep 30, 2024 | 21.37 Mn |
| Jun 30, 2024 | 25.17 Mn |
| Mar 31, 2024 | 22.05 Mn |
| Dec 31, 2023 | 19.39 Mn |
| Sep 30, 2023 | 16.45 Mn |
| Jun 30, 2023 | 20.67 Mn |
| Mar 31, 2023 | 21.18 Mn |
| Dec 31, 2022 | 19.56 Mn |
| Sep 30, 2022 | 30.37 Mn |
| Jun 30, 2022 | 31.16 Mn |
| Mar 31, 2022 | 30.56 Mn |
| Dec 31, 2021 | 36.58 Mn |
| Sep 30, 2021 | 29.14 Mn |